Prosecution Insights
Last updated: May 29, 2026
Application No. 18/042,779

OPHTHALMIC DYE

Non-Final OA §103§112
Filed
Feb 24, 2023
Priority
Aug 28, 2020 — EU 20193304.1 +1 more
Examiner
VU, JAKE MINH
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Vitreq B V
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
321 granted / 793 resolved
-19.5% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
31 currently pending
Career history
838
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
87.6%
+47.6% vs TC avg
§102
6.2%
-33.8% vs TC avg
§112
1.8%
-38.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 793 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of Applicant’s Restriction Requirement filed on 12/08/2025; and IDS filed on 02/24/2025. Claims 1-10, 16-19 are pending in the instant application. Claims 9-10, 16-19 are withdrawn from further consideration. Election/Restrictions Applicant’s election without traverse of Group I (claims 1-8) in the reply filed on 12/08/2025 is acknowledged. Claim Rejections - 35 USC § 112, 2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 4, the phrase “preferably” renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Note, withdrawn claim 10 has the same issue. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over YAMAMURA et al (JPH0894826). YAMAMURA teaches compound 23 (see pg. 9; wherein the compound is provided below with labels): PNG media_image1.png 234 423 media_image1.png Greyscale The difference between YAMAMURA’s compound and Applicant’s compound is R2, wherein YAMAMURA teaches R2 is C2, but Applicant claims one of the R2 has to be C1 or C3-8, which is only a difference of one CH2 group. Additionally, in Applicant’s claim 8, R1 is different by a single CH2 group. It would have been obvious to one of ordinary skill in the art to expect similar beneficial results with compounds having only additional -CH2- groups. Case laws holds that homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Thus, it would be presumed that the addition/subtraction of a single -CH2- group would possess similar properties. Telephonic Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAKE MINH VU whose telephone number is (571)272-8148. The examiner can normally be reached Mon-Fri 9:00am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAKE M VU/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Feb 24, 2023
Application Filed
Jan 05, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636365
MITOCHONDRION/RIBONUCLEIC ACID-TARGETED AND MIGRATABLE PHOTOSENSITIZED PROBE AND APPLICATION THEREOF
4y 8m to grant Granted May 26, 2026
Patent 12636254
STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION
2y 6m to grant Granted May 26, 2026
Patent 12629334
LIPID EMULSIONS AND USES THEREOF
3y 4m to grant Granted May 19, 2026
Patent 12594245
Dry Powder Formulations for Messenger RNA
3y 10m to grant Granted Apr 07, 2026
Patent 12584173
METHODS FOR DISEASE TREATMENT AND DRUG DISCOVERY
5y 1m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
68%
With Interview (+27.6%)
4y 1m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 793 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month